S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
Buy THIS stock before Taiwan is attacked (Ad)
UK travelers face hours-long waits for ferries to France
Intensity and insults rise as lawmakers debate debt ceiling
Unusual Passive Income Investment (Found on a Golf Course) (Ad)
Credit Suisse takeover hits heart of Swiss banking, identity
Small areas reopen near Fukushima nuclear plant, few return
Unusual Passive Income Investment (Found on a Golf Course) (Ad)
'War of the states': EV, chip makers lavished with subsidies
Lanterns and crescents: more retailers court Ramadan buyers
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
Buy THIS stock before Taiwan is attacked (Ad)
UK travelers face hours-long waits for ferries to France
Intensity and insults rise as lawmakers debate debt ceiling
Unusual Passive Income Investment (Found on a Golf Course) (Ad)
Credit Suisse takeover hits heart of Swiss banking, identity
Small areas reopen near Fukushima nuclear plant, few return
Unusual Passive Income Investment (Found on a Golf Course) (Ad)
'War of the states': EV, chip makers lavished with subsidies
Lanterns and crescents: more retailers court Ramadan buyers
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
Buy THIS stock before Taiwan is attacked (Ad)
UK travelers face hours-long waits for ferries to France
Intensity and insults rise as lawmakers debate debt ceiling
Unusual Passive Income Investment (Found on a Golf Course) (Ad)
Credit Suisse takeover hits heart of Swiss banking, identity
Small areas reopen near Fukushima nuclear plant, few return
Unusual Passive Income Investment (Found on a Golf Course) (Ad)
'War of the states': EV, chip makers lavished with subsidies
Lanterns and crescents: more retailers court Ramadan buyers
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
Buy THIS stock before Taiwan is attacked (Ad)
UK travelers face hours-long waits for ferries to France
Intensity and insults rise as lawmakers debate debt ceiling
Unusual Passive Income Investment (Found on a Golf Course) (Ad)
Credit Suisse takeover hits heart of Swiss banking, identity
Small areas reopen near Fukushima nuclear plant, few return
Unusual Passive Income Investment (Found on a Golf Course) (Ad)
'War of the states': EV, chip makers lavished with subsidies
Lanterns and crescents: more retailers court Ramadan buyers
TSE:REUN

Reunion Neuroscience - REUN Price Target & Analyst Ratings

C$0.93
-0.05 (-5.10%)
(As of 03/31/2023 12:00 AM ET)
Add
Compare
Today's Range
C$0.93
C$1.00
50-Day Range
C$0.93
C$1.84
52-Week Range
C$0.87
C$9.40
Volume
6,509 shs
Average Volume
8,514 shs
Market Capitalization
C$10.83 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Reunion Neuroscience Consensus Rating and Price Target (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Moderate Buy
Based on 3 Analyst Ratings

Consensus Analyst Price Target

C$15.50
1,566.67% Upside
High PredictionC$20.00
Average PredictionC$15.50
Low PredictionC$11.00
TypeCurrent
4/1/22 to 4/1/23
1 Month Ago
3/2/22 to 3/2/23
3 Months Ago
1/1/22 to 1/1/23
1 Year Ago
4/1/21 to 4/1/22
Consensus Rating
Moderate Buy
Buy
Buy
N/A
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
N/A
Buy
2 Buy rating(s)
2 Buy rating(s)
1 Buy rating(s)
N/A
Hold
1 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
N/A
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
N/A
Consensus Price TargetC$15.50C$15.50C$11.00N/A
Predicted Upside1,566.67% Upside751.65% UpsideN/AN/A
Get Reunion Neuroscience Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for REUN and its competitors with MarketBeat's FREE daily newsletter.

REUN Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

REUN Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Reunion Neuroscience Stock vs. The Competition

TypeReunion NeuroscienceMedical Companies
Consensus Rating Score
2.67
2.64
Consensus RatingModerate BuyBuy
News Sentiment RatingPositive News
Neutral News

Historical Target Prices and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
3/15/2023Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeSpeculative Buy ➝ Hold
1/19/2023HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Patrick Trucchio
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuyC$20.00+998.90%
12/16/2022Roth Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Elemer Piros
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuyC$11.00+110,000,000.00%
(Data available from 4/1/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)












REUN Price Target - Frequently Asked Questions

What is Reunion Neuroscience's consensus rating and price target?

According to the issued ratings of 3 analysts in the last year, the consensus rating for Reunion Neuroscience stock is Moderate Buy based on the current 1 hold rating and 2 buy ratings for REUN. The average twelve-month price prediction for Reunion Neuroscience is C$15.50 with a high price target of C$20.00 and a low price target of C$11.00. Learn more on REUN's analyst rating history.

Do Wall Street analysts like Reunion Neuroscience more than its competitors?

Analysts like Reunion Neuroscience more than other Medical companies. The consensus rating for Reunion Neuroscience is Moderate Buy while the average consensus rating for medical companies is Buy. Learn more on how REUN compares to other companies.

Is Reunion Neuroscience being downgraded by Wall Street analysts?

Over the previous 90 days, Reunion Neuroscience's stock had 1 downgrade by analysts.

Does Reunion Neuroscience's stock price have much upside?

According to analysts, Reunion Neuroscience's stock has a predicted upside of 751.65% based on their 12-month price targets.

What analysts cover Reunion Neuroscience?

Reunion Neuroscience has been rated by HC Wainwright, and Stifel Nicolaus in the past 90 days.


Stock Ratings Reports and Tools

This page (TSE:REUN) was last updated on 4/1/2023 by MarketBeat.com Staff